Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...
WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...
Some Canadians will be able to buy brand-name GLP-1 drug Ozempic at a reduced price, Danish drugmaker Novo Nordisk said in a statement Tuesday. The move comes as two generic versions of Ozempic and ...
The generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, Apotex You can save this article by ...
Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...
The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...
India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...
The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results